FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2978205889> ?p ?o ?g. }

• W2978205889 endingPage "S58" @default.
• W2978205889 startingPage "S57" @default.
• W2978205889 abstract "Purpose: To evaluate if appropriate dose titration of esomeprazole could control basal acid output (AO) in patients with documented ZES or IGH. Methods: This ongoing, 12-month, open-label, multicenter study (D9612C00025) included 19 patients with ZES and 2 patients with IGH. Patients were changed from their prior proton pump inhibitor therapy to esomeprazole 40 mg twice daily or 80 mg twice daily. At baseline and after 7–10 days, AO was evaluated by nasogastric aspiration and pH titration. Adequate control of AO was defined as AO <5 mmol/h and <10 mmol/h for patients who had and who had not had prior gastric-acid reducing surgery, respectively. Patients with controlled AO were maintained on the same dose, and AO was measured again at 3 and 6 months. If AO was not controlled, doses were uptitrated (to a maximum dose of 240 mg/d) until control was attained. At any time, doses could be increased at the investigator's discretion in patients reporting symptoms. Results: Of the 15 men and 6 women (mean age, 55 years; range, 42–72 years), 3 had multiple endocrine neoplasia type 1 (MEN-1) syndrome and 8 had metastatic ZE disease. None withdrew. AO was not controlled in 2 patients at some time during the study. At 6 months, AO was adequately controlled in 14 of 15 patients who received esomeprazole 40 mg twice daily. The AO of the other 6 patients was controlled with esomeprazole 80 mg twice daily (n = 5) or 80 mg 3 times daily (n = 1). Esomeprazole was generally well tolerated at all doses. Of the 4 serious adverse events reported, 1 (hypomagnesemia) was assessed as possibly drug-related but resolved without drug cessation. Conclusions: After the first 6 months in this ongoing study, maintenance esomeprazole treatment has effectively controlled AO in 95% of enrolled patients with ZES or IGH. Esomeprazole 40-mg, twice-daily is effective in 67% of these patients. These results suggest that esomeprazole is an effective medical therapy for patients with ZES. Supported by AstraZeneca LP.Table. Acid: Output (mmol/h)" @default.
• W2978205889 created "2019-10-10" @default.
• W2978205889 creator A5008374258 @default.
• W2978205889 creator A5010634985 @default.
• W2978205889 creator A5015987727 @default.
• W2978205889 creator A5017595887 @default.
• W2978205889 creator A5018989715 @default.
• W2978205889 creator A5030058343 @default.
• W2978205889 date "2005-09-01" @default.
• W2978205889 modified "2023-09-23" @default.
• W2978205889 title "Effects of Esomeprazole on Acid Output in Patients with Zollinger-Ellison Syndrome (ZES) and Idiopathic Gastric Acid Hypersecretion (IGH)" @default.
• W2978205889 doi "https://doi.org/10.14309/00000434-200509001-00104" @default.
• W2978205889 hasPublicationYear "2005" @default.
• W2978205889 type Work @default.
• W2978205889 sameAs 2978205889 @default.
• W2978205889 citedByCount "0" @default.
• W2978205889 crossrefType "journal-article" @default.
• W2978205889 hasAuthorship W2978205889A5008374258 @default.
• W2978205889 hasAuthorship W2978205889A5010634985 @default.
• W2978205889 hasAuthorship W2978205889A5015987727 @default.
• W2978205889 hasAuthorship W2978205889A5017595887 @default.
• W2978205889 hasAuthorship W2978205889A5018989715 @default.
• W2978205889 hasAuthorship W2978205889A5030058343 @default.
• W2978205889 hasConcept C126322002 @default.
• W2978205889 hasConcept C2777351272 @default.
• W2978205889 hasConcept C2777498785 @default.
• W2978205889 hasConcept C2777504413 @default.
• W2978205889 hasConcept C2778204628 @default.
• W2978205889 hasConcept C2779422922 @default.
• W2978205889 hasConcept C2781025758 @default.
• W2978205889 hasConcept C71924100 @default.
• W2978205889 hasConcept C90924648 @default.
• W2978205889 hasConceptScore W2978205889C126322002 @default.
• W2978205889 hasConceptScore W2978205889C2777351272 @default.
• W2978205889 hasConceptScore W2978205889C2777498785 @default.
• W2978205889 hasConceptScore W2978205889C2777504413 @default.
• W2978205889 hasConceptScore W2978205889C2778204628 @default.
• W2978205889 hasConceptScore W2978205889C2779422922 @default.
• W2978205889 hasConceptScore W2978205889C2781025758 @default.
• W2978205889 hasConceptScore W2978205889C71924100 @default.
• W2978205889 hasConceptScore W2978205889C90924648 @default.
• W2978205889 hasLocation W29782058891 @default.
• W2978205889 hasOpenAccess W2978205889 @default.
• W2978205889 hasPrimaryLocation W29782058891 @default.
• W2978205889 hasRelatedWork W1539130683 @default.
• W2978205889 hasRelatedWork W1576750010 @default.
• W2978205889 hasRelatedWork W2000425999 @default.
• W2978205889 hasRelatedWork W2010073807 @default.
• W2978205889 hasRelatedWork W2117466387 @default.
• W2978205889 hasRelatedWork W2159905106 @default.
• W2978205889 hasRelatedWork W2409351842 @default.
• W2978205889 hasRelatedWork W2414580964 @default.
• W2978205889 hasRelatedWork W2750456904 @default.
• W2978205889 hasRelatedWork W3137331026 @default.
• W2978205889 hasVolume "100" @default.
• W2978205889 isParatext "false" @default.
• W2978205889 isRetracted "false" @default.
• W2978205889 magId "2978205889" @default.
• W2978205889 workType "article" @default.